MED15 Involved in Head and Neck Squamous Cell Carcinoma

This article originally appeared here.
Share this content:
MED15 Involved in Head and Neck Squamous Cell Carcinoma
MED15 Involved in Head and Neck Squamous Cell Carcinoma

THURSDAY, April 2, 2015 (HealthDay News) -- The mediator subunit MED15 appears to be involved in head and neck squamous cell carcinoma (HNSCC), according to a study published in the April issue of The American Journal of Pathology.

Zaki Shaikhibrahim, Ph.D., from the University Hospital of Bonn in Germany, and colleagues examined the role of MED15 in HNSCC. They performed immunohistochemistry for MED15 on 324 tissue samples. MED15 knockdown was also performed, followed by proliferation and migration assays, as was transforming growth factor-β-1 (TGF-β1) treatment followed by MED15 analysis.

The researchers found that MED15 was overexpressed in 35, 30, and 70 percent of primary tumors, lymph node metastases, and recurrences, respectively, compared with no or low expression in benign tumors. In primary tumors from patients who developed recurrences, MED15 overexpression correlated with elevated mortality rates and was seen at the highest frequency in oral cavity or oropharyngeal tumors. There was a correlation for MED15 expression between primary tumors and corresponding lymph node metastases. TGF-β activity in tissues was associated with MED15; TGFβ activation led to increased MED15 expression and decreased pSMAD3 on MED15 knockdown.

"Taken together, our results implicate MED15 in HNSCC and hint that MED15 overexpression is a clonal event during HNSCC progression," the authors write. "MED15 may serve as a prognostic marker for recurrence and as a therapeutic target."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »